Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Price

Click to order products ascending

Display 15 Products per page

Aromatase Resistance and Palbociclib for Breast Cancer

$89.00

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.
April 1, 2014
Find out more
Macitenan for Pulmonary Arterial Hypertension

$89.00

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy
March 1, 2014
Find out more
Tyvaso for Pulmonary Arterial Hypertension

$89.00

The literature search was undertaken via multiple search engines and strategies with review of cited and associated articles to provide a comprehensive discussion on the topic. Expert opinion: While safe and well tolerated, inhaled treprostinil sodium should be limited, based on available data, to use as add-on therapy for patients with Group I pulmonary hypertension not effectively controlled on oral therapy.
November 29, 2016
Find out more
Palbociclib for Breast Cancer

$89.00

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
February 1, 2014
Find out more
Selexipag for Pulmonary Arterial Hypertension

$89.00

Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.
February 1, 2014
Find out more
Pacts in Medtech

$199.00

Pacts in Medtech – September/October 2016 – notable technology alliances, R&D partnerships and commercial collaborations disclosed in July and August 2016.
November 18, 2016
Find out more
Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.
October 21, 2015
Find out more
Inpatient Infections Pulse

$599.00

We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
October 8, 2014
Find out more
Biopharma Quarterly Dealmaking Statistics, Q3 2016

$499.00

A look at biopharma financing, M&A and alliance activity July–September 2016, based on data from Strategic Transactions.
November 18, 2016
Find out more
2015 Post-AAIC KOL Interview

$599.00

Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.
August 1, 2015
Find out more
Acute Myelogenous Leukemia (AML) KOL Interview

$599.00

Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.
August 19, 2016
Find out more
Post-EASL KOL Interview

$599.00

Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]
May 29, 2015
Find out more
2015 PCSK9 Inhibitors Pulse

$599.00

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.
August 19, 2015
Find out more
Breast Cancer Pulse #2

$599.00

We performed a 5-question survey of 24 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs and drug candidates discussed: •Neratinib, PBYI •Herceptin (trastuzumab), Roche •Perjeta (pertuzumab), Roche •Kadcyla (trastuzumab-DM1), Roche •Tykerb (lapatinib), GSK
October 31, 2016
Find out more
Breast Cancer Pulse #1

$599.00

We performed a 5-question survey of 22 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs discussed: •Ibrance (palbociclib, PFE) •Afinitor (everolimus, NVS) •Halaven (eribulin, Eisai) •Abraxane (nab-paclitaxel, CELG) •Doxil (pegylated liposomal doxorubicin, JNJ) •Gemzar (gemcitabine, LLY) •Xeloda (capecitabine, Roche)
October 31, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *